文献速递心律失常血脂与心血管预防

抗凝房颤患者左心房血栓患病率的Meta分析

Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该系统评价与Meta分析纳入35项研究共14653例接受指南指导抗凝至少3周的房颤/房扑患者,左心房血栓平均加权患病率为2.73%。非阵发性房颤/房扑、CHA2DS2-VASc评分≥3及拟行心脏复律者的血栓患病率显著更高,提示部分高危亚组可能从常规术前经食管超声中获益。

要点

  • 抗凝房颤/房扑患者左心房血栓总体患病率约2.73%。
  • 非阵发性房颤/房扑患者血栓患病率约为阵发性的4倍。
  • CHA2DS2-VASc≥3或拟行复律者血栓风险更高,或需术前TEE。

核心结论

  • 在接受指南指导抗凝的房颤/房扑患者中,左心房血栓在部分高危亚组中患病率较高,这些患者可能从心脏复律或导管消融前常规经食管超声检查中获益。

研究设计与样本

  • 系统检索EMBASE、MEDLINE和CENTRAL自建库至2020年7月的研究,纳入报告房颤/房扑患者接受至少3周连续治疗性口服抗凝(维生素K拮抗剂或直接口服抗凝药)后经食管超声检出左心房血栓患病率的研究。
  • 共纳入35项研究,描述14653例患者,采用随机效应模型进行Meta分析。

主要发现

  • 左心房血栓平均加权患病率为2.73%(95%CI:1.95%至3.80%)。
  • 维生素K拮抗剂与直接口服抗凝药治疗患者的左心房血栓患病率相似(2.80%;95%CI:1.86%至4.21% vs. 3.12%;95%CI:1.92%至5.03%;p=0.674)。
  • 非阵发性房颤/房扑患者左心房血栓患病率显著高于阵发性患者(4.81%;95%CI:3.35%至6.86% vs. 1.03%;95%CI:0.52%至2.03%;p<0.001)。
  • 拟行心脏复律者左心房血栓患病率显著高于拟行消融者(5.55%;95%CI:3.15%至9.58% vs. 1.65%;95%CI:1.07%至2.53%;p<0.001)。
  • CHA2DS2-VASc评分≥3者左心房血栓患病率显著高于评分≤2者(6.31%;95%CI:3.72%至10.49% vs. 1.06%;95%CI:0.45%至2.49%;p<0.001)。

临床怎么用

  • 对于接受指南指导抗凝的房颤/房扑患者,应评估非阵发性房颤、CHA2DS2-VASc评分≥3及拟行心脏复律等高危因素,以决定心脏复律或导管消融前是否行经食管超声检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of left atrial (LA) thrombus in patients with atrial fibrillation (AF) or atrial flutter (AFL) on guideline-directed anticoagulation is not well known, yet this may inform transesophageal echocardiogram (TEE) use before cardioversion or catheter ablation. OBJECTIVES: The purpose of this study was to quantify LA thrombus prevalence among patients with AF/AFL on guideline-directed anticoagulation and to identify high-risk subgroups. METHODS: EMBASE, MEDLINE, and CENTRAL were systematically searched from inception to July 2020 for studies reporting on LA thrombus prevalence among patients with AF/AFL undergoing TEE following at least 3 weeks of continuous therapeutic oral anticoagulation with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). Meta-analysis was performed using random effects models. RESULTS: Thirty-five studies describing 14,653 patients were identified. The mean-weighted LA thrombus prevalence was 2.73% (95% confidence interval [CI]: 1.95% to 3.80%). LA thrombus prevalence was similar for VKA- and DOAC-treated patients (2.80%; 95% CI: 1.86% to 4.21% vs. 3.12%; 95% CI: 1.92% to 5.03%; p = 0.674). Patients with nonparoxysmal AF/AFL had a 4-fold higher LA thrombus prevalence compared with paroxysmal patients (4.81%; 95% CI: 3.35% to 6.86% vs. 1.03%; 95% CI: 0.52% to 2.03%; p < 0.001). LA thrombus prevalence was higher among patients undergoing cardioversion versus ablation (5.55%; 95% CI: 3.15% to 9.58% vs. 1.65%; 95% CI: 1.07% to 2.53%; p < 0.001). Patients with CHA2DS2-VASc scores ≥3 had a higher LA thrombus prevalence compared with patients with scores ≤2 (6.31%; 95% CI: 3.72% to 10.49% vs. 1.06%; 95% CI: 0.45% to 2.49%; p < 0.001). CONCLUSIONS: LA thrombus prevalence is high in subgroups of anticoagulated patients with AF/AFL, who may benefit from routine pre-procedural TEE use before cardioversion or catheter ablation.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lurie A, Wang J, Hinnegan KJ, et al. Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2021. PMID: 34112315. doi:10.1016/j.jacc.2021.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。